Press release Biocartis NV

Biocartis Hosts Corporate Workshop and Announces Seven Idylla Abstracts to be Presented at AMP 2023 Annual Meeting

PRESS RELEASE - 13 November 2023, 07:00 CET

Biocartis Hosts Corporate Workshop and Announces Seven Idylla Abstracts to be Presented at AMP 2023 Annual Meeting

Mechelen, Belgium and Itasca (IL), United States, 13 November 2023 – Biocartis, an innovative molecular diagnostics company, announces today that it will host a free corporate workshop at the Annual Meeting of the ‘Association for Molecular Pathology’ (AMP), a leading molecular diagnostics conference, taking place between 14-18 November 2023 in Salt Lake City, Utah (US). In addition, seven abstracts that used the Idylla Platform and were performed by a variety of US laboratories and research institutes will be presented at this conference.

The workshop (15 November 2023, 14:00-14:50 MST) will focus on how patient management in personalized medicine can be expedited with rapid molecular tests. Dr. Tejus A. Bale (MD, PhD), Neuropathologist & Diagnostic Molecular Pathologist at Memorial Sloan Kettering Cancer Center (MSKCC), a world leading cancer center in New York, will present her experiences with rapid testing for IDH1-2 mutations. The workshop will also feature a panel discussion with Dr. Tejus A. Bale and Julie Ramage, Principal and Founder, Harbor Precision Genomics Consulting. Together, they will discuss how a fully automatic system can enable rapid and accurate identification of actionable biomarkers.

Among the seven abstracts published, three abstracts focus on the various uses of the Idylla BRAF Mutation Assay¹, including a study on the potential benefits of rapid screening for BRAF V600E mutations in acute myeloid leukemia (AML). Two other abstracts focus on the Idylla MSI Test² and confirm the Test’s specificity for dMMR (mismatch repair deficiency) screening for colorectal cancer and show improved specificity and accuracy versus NGS methods. Another abstract demonstrates that Idylla KRAS Mutation Assay³ Cartridges, even though designed for formalin-fixed, paraffin-embedded tissue (FFPE), can also be used for analysis of pancreatic cyst aspirates, thereby confirming the versatility of the Idylla System. In the last abstract, the performance of the Idylla IDH1-2 Mutation Assay Kit⁴ in glioma FFPE biopsy samples was analyzed. This study showed that the Idylla IDH1-2 Mutation Assay Kit provided rapid results with a high concordance versus NGS methods.